Skip to main content

Table 4 Published results of clinical trials on the use of CD47 antagonists in hematological tumors

From: The landscape overview of CD47-based immunotherapy for hematological malignancies

Drug Name

NCT Number

Sponsor

Protocol

Indication Detail

Enroll-ment

Age/Race/Healthy Volunteers

Phase

Status

Start Date

Design

Endpoint Types

Efficacy Results

Ref

CC-90002

NCT02641002

Celgene Corp

CC-90002

Subjects With AML and High-Risk MDS

28

Adults (18 and over)

Phase I

Terminted

2016/3/1

Interventional; Treatment; Open Label; Single Group Assignment

Safety; Efficacy; Pharmacokinetics

terminated (preliminary monotherapy data did not offer a sufficiently encouraging profile for further dose escalation/expansion)

[61]

TJ011133

NCT04202003

I-Mab Biopharma Co Ltd

TJ011133

r/r AML/MDS

5

Adults (18–79 years)

Phase I

Recruiting

2020/3/25

Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment

Efficacy

20% achieved morphologic leukemia-free state

[62]

Hu5F9-G4

NCT03248479

Gilead Sciences Inc

Hu5F9-G4; AZA

untreated AML/MDS

68

Adults (18 and over)

Phase I

Recruiting

2017/9/8

Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment

Safety; Efficacy; Pharmacokinetics

ORR: 79%; CR/CRi: 56%

[63]

Hu5F9-G4

NCT04435691

MD Anderson Cancer Center

Hu5F9-G4; AZA; VEN

Patients (pts) with Newly Diagnosed AML

23

Adults (18 and over)

Phase I/II

Recruiting

2020/7/28

Interventional; Treatment; Open Label; Single Group Assignment

Safety; Efficacy

CR/CRi: 100%

[64]

Hu5F9-G4

NCT04435691

MD Anderson Cancer Center

Hu5F9-G4; AZA; VEN

Patients (pts) with R/R-post-VEN failure AML

13

Adults (18 and over)

Phase I/II

Recruiting

2020/7/28

Interventional; Treatment; Open Label; Single Group Assignment

Safety; Efficacy

CR/CRi: 27%

[64]

Hu5F9-G4

NCT04435691

MD Anderson Cancer Center

Hu5F9-G4; AZA; VEN

Patients (pts) with R/R-VEN naive AML

8

Adults (18 and over)

Phase I/II

Recruiting

2020/7/28

Interventional; Treatment; Open Label; Single Group Assignment

Safety; Efficacy

CR/CRi: 63%

[64]